Analyst: Genmab share price may double
In an analysis, Jyske Bank estimates that Genmab's stock price does not reflect the potential of the company's pipeline, although it highlights one large risk within this share.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Genmab has struggled so far in 2021, but certain signs indicate the share may be regaining its momentum, according to an analysis from the Danish bank Jyske Bank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA grants new Genmab drug priority review status
For subscribers
.jpg&w=384&q=75)
